Is GSK (LSE:GSK) Still Reasonable, Or Is The Value Already Priced In?

GSK stock has delivered a strong 54.4% gain over the past 5 years, yet the current checks still flag it as looking cheap rather than stretched on valuation grounds.

• The 54.4% total return over 5 years points to investors already being rewarded, so the key issue now is whether that run has already captured most of the easy value in GSK.
• Future cash generation from its pharmaceuticals and vaccines portfolio can support a higher valuation. At the same time, ongoing execution and regulatory risks may limit how much investors are willing to pay for those earnings.
• On a broad set of valuation checks GSK screens as undervalued, with a high value score of 5 out of 6 suggesting the stock leans cheap rather than fully priced.

The issue now is whether GSK’s current share price already reflects these strengths or if there is still a meaningful discount for patient investors.

Spot opportunities beyond GSK's current valuation story by checking stocks that also screen as potentially mispriced using 9 high quality undervalued stocks.

Is GSK Still Cheap on Earnings?

The P/E ratio is a useful anchor for GSK because earnings are a key driver of how investors value large pharmaceutical stocks. GSK currently trades on a P/E of 15.6x, which is well below the wider pharmaceuticals industry average of 22.2x and also below the peer group average of 43.1x. That gap suggests the market is putting a lower earnings multiple on GSK than on many comparable companies in the sector.

The Fair Ratio for GSK is 35.1x, which reflects what investors might typically pay for a company with its mix of growth prospects, margins, size and risks. Set against that benchmark, the current 15.6x multiple implies a sizeable discount, since the stock trades at less than half of this tailored fair value marker. For investors who focus on earnings based valuation, GSK therefore appears to offer exposure to the sector at a P/E that screens as relatively low.

On the P/E multiple, GSK stock looks undervalued compared with both its Fair Ratio and wider pharmaceutical peers.

See what the numbers say about this price — find out in our valuation breakdown.

The GSK Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for GSK pick up where the valuation checks leave off and explain which combinations of GSK's future growth, margins and earnings would justify a materially higher or lower share price than today. Rather than relying on a single multiple or model output, each narrative sets out the key assumptions behind its view of fair value so you can compare those expectations with GSK's actual results over time.

Community views on GSK are split between a refreshed growth story and concerns that risks still outweigh the upside.

Bull case: 13% undervalued

"GSK is well-positioned to benefit from the global rise in demand for vaccines and specialty medicines, driven by an aging population and higher healthcare access in emerging markets, evidenced by robust ongoing growth in Shingrix, meningitis vaccines, and double-digit expansion in specialty medicines, which supports sustained revenue growth and greater resilience in future cash flows..."

Read the full Bull Case to see why GSK could be undervalued

Bear case: 29% overvalued

"GSK's future revenue growth and profit margins will be severely constrained as governments and private payors accelerate cost containment measures and implement additional pricing pressures, especially in key markets such as the U.S. and Europe, undermining the company's ability to monetize new launches or sustain premium pricing on specialty and vaccine products..."

Read the full Bear Case to see why GSK could be overvalued

Do you think there's more to the story for GSK? Head over to our Community to see what others are saying!

The Bottom Line

For GSK, the current picture leans towards undervalued on earnings, with the P/E still sitting well below sector and tailored fair ratio benchmarks. The key question is whether that discount reflects lingering concern over execution and regulatory risk or an opportunity for investors willing to accept those uncertainties. From here, the outcome largely hinges on whether GSK can convert its pharmaceuticals and vaccines pipeline into consistent earnings that convince the market to lift the multiple instead of continuing to price in a risk discount.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com